Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 3/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.61 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.56 |
| ▸ | CTSL | P07711 | 4/20 | 0.49 |
| ▸ | CTSK | P43235 | 4/20 | 0.49 |
| ▸ | CTSB | P07858 | 3/20 | 0.48 |
| ▸ | TACR1 | P25103 | 2/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7361850 | 1.00 | CTRB1 (0.64) | CTRB1OPRK1ITGB3ITGA2BCTSL | |
| SCHEMBL18132975 | 0.93 | CTRB1 (0.56) | CTRB1OPRK1ITGB3ITGA2BCTSL | |
| SCHEMBL19043611 | 0.91 | ITGB3 (0.56) | CTRB1OPRK1ITGB3ITGA2BCTSL | |
| SCHEMBL7398974 | 0.89 | CTRB1 (0.60) | CTRB1OPRK1ITGB3ITGA2BCTSL | |
| SCHEMBL7398976 | 0.89 | CTRB1 (0.60) | CTRB1OPRK1ITGB3ITGA2BCTSL | |
| SCHEMBL14069202 | 0.89 | CTRB1 (0.60) | CTRB1OPRK1ITGB3ITGA2BCTSL | |
| SCHEMBL6588325 | 0.87 | CTRB1 (0.57) | CTRB1OPRK1ITGB3ITGA2BCTSL | |
| SCHEMBL16419142 | 0.82 | OPRK1 (0.63) | CTRB1OPRK1ITGB3ITGA2BCTSL | |
| SCHEMBL16421364 | 0.82 | OPRK1 (0.63) | CTRB1OPRK1ITGB3ITGA2BCTSL | |
| SCHEMBL30757694 | 0.81 | ATM (0.60) | OPRK1CTSLCTSKCTSBACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013000-B2 | 3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimlant activity | ALLERGAN, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20080312236-A1 | 3-Heteroaryl-3-Hydroxy-2-Amino-Propyl Amines And Related Compounds Having Analgesic And/Or Immuno Stimlant Activity | EXONHIT THERAPEUTICS SA (FR) | 2008-12-18 | — | — | US | disclosed |
| WO-1997046553-A1 | THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312236-A1 | 3-Heteroaryl-3-Hydroxy-2-Amino-Propyl Amines And Related Compounds Having Analgesic And/Or Immuno Stimlant Activity | OPRL1, OPRM1, MRGPRX2 | CTRB1 4669/4885OPRK1 8/4885ITGB3 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.